NCT03408587View on ClinicalTrials.gov

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 29, 2018

Primary Completion Date

May 22, 2019

Study Completion Date

May 22, 2019

Conditions
Uveal MelanomaLiver Metastases
Interventions
BIOLOGICAL

CVA21

Oncolytic virus

BIOLOGICAL

Ipilimumab

Fully human IgG1 monoclonal antibody that binds to the CTLA-4 receptor expressed on activated T cells.

Trial Locations (3)

33140

Mount Sinai Medical Center, Miami Beach

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Viralytics
All Listed Sponsors
lead

Viralytics

INDUSTRY

NCT03408587 - CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) | Biotech Hunter | Biotech Hunter